The real reason small-cap stocks win out
A US physicist has turned his attention to biology in order to explain why small companies grow faster than big ones. The results are compelling, says Tim Bennett.
Jim Slater, one of Britain's best-known investors, summed up the reasons behind his preference for small caps in one line: "Elephants don't gallop." His point was that, if you're looking for rapid share-price gains in the short term, it's a lot easier for a small company to double in size, than for a large rival.
But it's not just the short term. Several studies on both sides of the Atlantic have demonstrated that, over the long run, small caps deliver better returns (on average) than large caps.
The usual reason given for this small-cap premium' is that shares in small, fast-growing companies are riskier they go bust more quickly and more often, so you expect a higher return. But as Robert P Seawright, chief investment officer at Madison Avenue Securities, notes on Rpseawright.wordpress.com, a physicist called Geoffrey West has an alternative explanation for just why small is beautiful.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Applying biology to finance
West is a renowned physicist who, as Seawright notes, has "always wanted to find rules that govern everything". His quest has taken him beyond physics and into biology, where he claims there is one "overarching lesson": that "as organisms grow in size they become more efficient".
Large animals use energy more effectively by employing what economists call economies of scale. This is why big animals live longer than little ones: "life span, lifetime number of heartbeats, metabolic rate and many other measures scale with body mass".
Applying this argument to companies, this might seem to suggest you should invest in larger ones they're more, efficient after all.
But here's the rub while "all mammals grow and develop quickly early on", that growth will "flatten out over time". In other words, most of the growth is done in the early stages of an organism's life span.
The reason this matters for investors is that companies show a remarkably similar pattern of growth over their typical life span of 40-50 years. West looked at the growth curves for thousands of publicly traded US companies. He used a wide range of variables, including valuation, assets, revenue, profits and employees.
While he found that sales do increase linearly with size (ie, roughly one-for-one), profits don't indeed, they decrease relative to sales.
So while a firm may grow in size from 100 to 1,000,000 employees, its profits won't grow at the same rate they will only grow at a ratio of roughly 0.8:1. In other words, like animals, companies are destined to grow fast for a while before slowing down, then declining and dying.
Bureaucracy kills innovation
So why does this happen in companies? West's key observation, says Seawright, is that "as companies grow, they become dominated primarily by infrastructure rather than people, and by economies of scale rather than innovation".
In short, as firms sacrifice "creativity and innovation" to "bureaucracy and administration", they are overtaken by younger firms and eventually vanish altogether. Says West: "companies are killed by their need to keep on getting bigger".
This suggests that the premium attached to small firms isn't just about risk. It turns out that size is, in itself, a drag on productivity and profits. So favouring small caps makes sense. My colleague Tom Bulford writes on these regularly in his free email, The Penny Sleuth.
This article is taken from Tom Bulford's free twice-weekly small-cap investment email The Penny Sleuth. Sign up to The Penny Sleuth here.
Information in Penny Sleuth is for general information only and is not intended to be relied upon by individual readers in making (or not making) specific investment decisions. Penny Sleuth is an unregulated product published by Fleet Street Publications Ltd.
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
Tim graduated with a history degree from Cambridge University in 1989 and, after a year of travelling, joined the financial services firm Ernst and Young in 1990, qualifying as a chartered accountant in 1994.
He then moved into financial markets training, designing and running a variety of courses at graduate level and beyond for a range of organisations including the Securities and Investment Institute and UBS. He joined MoneyWeek in 2007.
-
GSK share price surges after $2.2bn Zantac drug settlement
GSK has settled lawsuits in the US that alleged the drugmaker’s now-discontinued heartburn drug Zantac triggered cancer
By Chris Newlands Published
-
Will the Autumn Budget impact investment markets?
Keir Starmer has warned the Autumn Budget will be “painful”. Will it impact investment markets and should you tweak your portfolio before 30 October?
By Katie Williams Published
-
Somero: trading this overlooked bargain
Features Mechanical-screed maker Somero dominates its niche and is attractively valued. Matthew Partridge picks the best way to trade it.
By Dr Matthew Partridge Published
-
How to find big profits in small companies
Cover Story The small- and micro-cap sectors are risky and volatile. But with careful research and patience, investors could make huge gains. Matthew Partridge explains how to find the market’s top tiddlers.
By Dr Matthew Partridge Published
-
The hidden gems on Aim, London's junior market
Features Aim, London’s junior market, is risky – but you can find solid stocks at low prices. Scott Longley reports.
By Scott Longley Published
-
Is Aim finally coming of age?
Features The Aim market of mostly smaller companies has traditionally been seen as a bit of a backwater. Is it time to change that view? Matthew Partridge talks to Paul Latham and Richard Power of fund management company Octopus.
By Dr Matthew Partridge Published
-
Fetch! The Chinese small-cap stocks to buy in the Year of the Dog
Opinion Each week, a professional investor tells us where she’d put her money. This week: Tiffany Hsiao of Matthews Asia selects three Chinese small-cap stocks with exciting potential.
By Tiffany Hsio Published
-
Small and mid-cap stocks with big potential
Opinion Professional investor Guy Anderson of the Mercantile Investment Trust selects three small and medium-sized firms with promising prospects that the market has missed.
By Guy Anderson Published
-
Get cheap, reliable growth from smaller companies
Features One of the most reliable long-term investment trends is the long-term outperformance of smaller companies over blue chips. Max King picks some of the best ways to buy into this growth.
By Max King Published
-
Big gains from small caps
Features In an environment of middling inflation and low interest rates, small-cap stocks tend to beat big blue-chips. John Stepek explains why, and how to invest in them.
By John Stepek Published